A 25-gene classifier predicts overall survival in resectable pancreatic cancer.

ABSTRACT:

Background

Pancreatic carcinoma is one of the most lethal human cancers. In patients with resectable tumors, surgery followed by adjuvant chemotherapy is the only curative treatment. However, the 5-year survival is 20%. Because of a strong metastatic propensity, neoadjuvant chemotherapy is being tested in randomized clinical trials. In this context, improving the selection of patients for immediate surgery or neoadjuvant chemotherapy is crucial, and high-throughput molecular analyses may help; the present study aims to address this.

Methods

Clinicopathological and gene expression data of 695 pancreatic carcinoma samples were collected from nine datasets and supervised analysis was applied to search for a gene expression signature predictive for overall survival (OS) in the 6

SUBMITTER: Birnbaum DJ 

PROVIDER: S-EPMC5606023 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature